The funds will be used to complete the manufacture and CE marking of its Ultravision technology prior to its planned launch in the second half of 2013.
Ultravision — a smoke clearance device in which electrosurgical smoke is cleared from minimal access and open surgical procedures — is one product in a range of laparoscopic surgery devices being developed by Asalus.
Asalus’s two other products are Surehold, a multi-functional device for the atraumatic manipulation of tissues and organs; and Snugport, a laparoscopic access port that is claimed to provide significant benefits over those currently on the market.
The £1.25m funding includes investments from existing investors Fusion, Finance Wales and IP Group.
As a result of the funding, Fusion will own a 44 per cent undiluted shareholding in Asalus.
UK productivity hindered by digital skills deficit – report
This is a bit of a nebulous subject. There are several sub-disciplines of 'digital skills' which all need different approaches. ...